COMP360 showed rapid and durable efficacy in highly treatment-resistant depression, with about 40% of patients achieving meaningful response and a favorable safety profile through 26 weeks. Regulatory review is underway, with anticipated U.S. launch in 2027 and strong stakeholder enthusiasm for this differentiated treatment.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.